Submitted: 30 Apr 2018
Accepted: 20 Aug 2018
First published online: 14 May 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Shahrekord Univ Med Sci. 2019;21(1):39-44.
  Abstract View: 81
  PDF Download: 68

Original Article

Effect of valproic acid on cisplatin-resistant ovarian cancer cell lines

Somayeh Hashemi-Sheikhshabani 1 ORCiD, Zeinab Amini-Farsani 2, Mehdi Shamsara 3, Zahra Sajadpoor 1, Mohammad Hossein Sangtarash 4, Hossein Teimori 1 * ORCiD

1 Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Young Researchers and Elites Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
3 National Research Center for Transgenic Mouse, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
4 Department of Biology, University of Sistan and Baluchestan, Zahedan, Iran
*Corresponding Author: Hossein Teimori, Tel: +98-381-3346692, Fax: +98-381-3330709, Email: Email: hteimori@skums.ac.ir

Abstract

Background and aims: Platinum resistance has been one of the most important problems in the management of ovarian cancer. The effects of various chemotherapeutic agents are limited in patients with platinum resistance. Therefore, developing new anticancer drugs that can improve the effect of currently used cytostatics is critical. The current study investigated the effects of valproic acid (VPA) alone and in combination with cisplatin on ovarian cancer cells.

Methods: In this experimental study, the human ovarian cancer cell lines (A2780-S and A2780-CP) were grown in RPMI-1640 medium in appropriate culture conditions. The cells were treated with various concentrations of cisplatin (0.15-400 µg/mL) or VPA (10-2000 µg/mL) and were incubated for 24, 48, and 72 hours. Moreover, A2780 cells were co-treated with different concentrations of cisplatin and VPA for 48 hours. Afterward, cell viability was investigated using MTT assay. GraphPad Prism statistical software was used for the data analysis and ANOVA and Duncan’s test were conducted.

Results: A dose- and time-dependent reduction was observed in cell viability following the treatment with cisplatin or VPA. Moreover, cotreatment of the A2780 cells with cisplatin and VPA resulted in a significantly greater inhibition of cell viability compared to the treatment with either agent alone.

Conclusion: Overall, it can be argued that VPA does not only cause inhibition of proliferation and induction of apoptosis in ovarian cancer cells but also helps to enhance the antiproliferative effects of cisplatin and results in the increased susceptibility to cisplatin in resistant cells. VPA may therefore be used to treat cancer in the future.

First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 81

Your browser does not support the canvas element.


PDF Downloaded: 68

Your browser does not support the canvas element.